Holen Sie sich die Stockscreener-App
6.02
3.44%
0.20
Vorhandelsmarkt:
6.02
Schlusskurs vom Vortag:
$5.82
Offen:
$5.82
24-Stunden-Volumen:
1.49M
Relative Volume:
0.34
Marktkapitalisierung:
$575.81M
Einnahmen:
$829.00M
Nettoeinkommen (Verlust:
$-399.90M
KGV:
-1.3948
EPS:
-4.3159
Netto-Cashflow:
$-23.20M
1W Leistung:
+8.66%
1M Leistung:
+44.36%
6M Leistung:
+24.64%
1J Leistung:
-25.68%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$5.39
$6.07
52-Wochen-Spanne:
$2.74
$8.50
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.02 | 575.81M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
684.89 | 253.24B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.97 | 163.77B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
404.90 | 58.36B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.96 | 49.61B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
273.60 | 45.03B | 16.63B | 1.39B | 2.12B | 8.0674 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-20 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2026-09-09 | Fortgesetzt | UBS | Neutral |
| 2026-09-01 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Labcorp to buy Myriad’s prenatal health testing unit for $210M - MedTech Dive
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers - The Manila Times
Myriad Genetics presents data on cancer recurrence detection test By Investing.com - Investing.com Canada
Myriad Genetics releases MRD cancer detection data at ESMO 2026 - StreetInsider
Myriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions - Yahoo Finance
Myriad Genetics: Prenatal Sale Provides A Lifeline In A Tough Spot (NASDAQ:MYGN) - Seeking Alpha
Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner - Yahoo Finance
Myriad Genetics to present at Wells Fargo healthcare conference - scanx.trade
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance Singapore
Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner - FinancialContent
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Yahoo Finance
Form 8K Myriad Genetics Inc For: 20 October By Investing.com - Investing.com Nigeria
Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business - Investorideas.com
Why Is Myriad Genetics Stock Trading Higher Today?Myriad Genetics (NASDAQ:MYGN) - Benzinga
Current ratio of Myriad Genetics, Inc. – XETR:MYD - TradingView
Myriad Genetics stock surges on $210M prenatal unit sale - Yahoo Finance Singapore
Myriad Genetics stock surges on $210M prenatal unit sale - Investing.com
Myriad Genetics (MYGN) Shares Surge 20% Premarket on Prenatal He - GuruFocus
Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday - Benzinga
Myriad Genetics to Sell Prenatal Testing Business to Labcorp for $210M - GenomeWeb
Myriad to sell prenatal health business to Labcorp (MYGN:NASDAQ) - Seeking Alpha
MYGN Stock Draws Bullish Targets As Prostate Cancer Push Builds - Timothy Sykes
MYGN Stock Draws Bullish Targets As Oncology Pivot Accelerates - StocksToTrade
Why is Myriad Genetics stock surging today? - Investing.com
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp - The Manila Times
Form 8K Myriad Genetics Inc For: 20 October By Investing.com - Investing.com India
Myriad Genetics to Sell Prenatal Health Division to LabCorp for $210 Million Cash - Kalkine Media
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp - Yahoo Finance
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know - Yahoo Finance
Myriad Genetics, Inc. (MYGN) Stock Forecasts - Yahoo Finance
Myriad Genetics to report Q3FY26 results on November 4, 2026 - scanx.trade
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 - Yahoo Finance
What Myriad Genetics Doubters Saw Before The Drop - Yahoo Finance
SOPHiA GENETICS, Myriad Genetics and AstraZeneca Collaborate to Advance Precision Oncology in Prostate Cancer - BioPharma APAC
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology - PR Newswire
MYRIAD GENETICS INC MYRIAD GENE (0K3W.L) Q2 FY2026 earnings call transcript - Yahoo Finance
Craig-Hallum raises target for Myriad Genetics stock from USD 4.00 to USD 8.00 - AD HOC NEWS
Craig-Hallum raises target for Myriad Genetics stock from USD 4.00 to USD 8.00 - AD HOC NEWS
Myriad Genetics, Inc. (0K3W.L) stock price, news, quote and history - Yahoo Finance UK
Myriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split Targets - Yahoo Finance
Myriad Genetics (Nasdaq:MYGN)Stock Analysis - Simply Wall Street
Why Is Myriad Genetics (MYGN) Stock Soaring Today - FinancialContent
Why Is Myriad Genetics (MYGN) Stock Soaring Today - Yahoo Finance
Myriad Genetics, Inc. (MYGN) Stock Forecasts - Yahoo Finance
Form 4 Myriad Genetics Inc For: 27 September By Investing.com - Investing.com South Africa
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.
Myriad Genetics (MYGN) ex-CCO keeps stock-tied PSUs - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating the Challenges in Diagnostics & Research - DirectorsTalk Interviews
Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset - Yahoo Finance
Myriad Genetics (NASDAQ: MYGN) swaps commercial chief but keeps 2026 outlook - Stock Titan
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Myriad Genetics Inc-Aktie (MYGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kumar Rashmi | Director |
Jun 08 '26 |
Proposed Sale |
4.59 |
15,000 |
68,850 |
0 |
| Bisaro Paul | Director |
May 14 '26 |
Buy |
3.69 |
7,500 |
27,638 |
97,441 |
| Raha Samraat S. | President and CEO |
Mar 09 '26 |
Buy |
5.00 |
40,000 |
199,844 |
493,104 |
| Phanstiel S. Louise | Director |
Feb 27 '26 |
Buy |
4.66 |
48,000 |
223,728 |
281,951 |
| Phanstiel S. Louise | Director |
Feb 26 '26 |
Buy |
4.80 |
50,407 |
242,105 |
233,951 |
| Phanstiel S. Louise | Director |
Feb 25 '26 |
Buy |
4.74 |
6,100 |
28,890 |
183,544 |
0.60%
5.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):